Navigation Links
Hepatitis in Biological Technology

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

... licensed the exclusive worldwide rights to novel hepatitis C Virus (HCV) technology from Stanford ... future cocktails for HCV therapy." About hepatitis C Virus Infections from HCV have reached ... agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes ...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been ... used in combination in a Phase II trial to treat hepatitis C patients. This trial incorporates several ... Status from the FDA for the treatment of chronic hepatitis C. About Anadys Anadys ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... developing novel medicines for the treatment of hepatitis C, today reported its financial results and ... development of ANA598 as a treatment for chronic hepatitis C," said Steve Worland, Ph.D., President and CEO ... Phase I clinical trial for the treatment of hepatitis C. During the second quarter of 2008, ANA773 ...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

... developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which ... polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the ...

Schering-Plough Reports Financial Results for 2009 Second Quarter

... boceprevir, a protease inhibitor in Phase III for hepatitis C; and BRIDION (sugammadex), an innovative agent ... U.S. and Japan. Sales of PEGINTRON for hepatitis C decreased 6 percent to $215 million in the 2009 ... SPRINT-1 study showing that boceprevir, an oral hepatitis C protease inhibitor, in combination with ...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

... with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 ... patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and ... 170 million people worldwide are infected with hepatitis C virus, including nearly four million in the ...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

... Approximately 50% of patients with chronic hepatitis C fail to respond to their initial course of ... by visiting www.infergen.com . About hepatitis C hepatitis means inflammation of the ....

Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program

... level to the state level which treats chronic hepatitis B, a condition which affects 10% of the ... success from its flagship Xin Ao Xin Oleanholic hepatitis B product to create a diversified product base addressing multiple indications. hepatitis B affects 10% of the Chinese population. This ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with ... data from current cohorts in ongoing studies in hepatitis C and oncology, Anadys intends to manage the ... is preparing for the first Phase II trial in hepatitis C patients of ANA598 in combination with ...

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study

... is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. ... ribavirin as a cornerstone in the treatment of hepatitis C, but with the advantage of less anemia," said ... the potential for taribavirin in the treatment of hepatitis C, the continuing role of ribavirin or ...

Veteran-Owned Biotech Startup Company Charges Health Agency (NYSDOH) with Blackballing its Initiatives

... world-first U.S.-Egyptian collaborative study on hepatitis C and blood ozonation." This contracted study ... is overwhelmed with the highest prevalence of hepatitis C in the world. Furthermore, the fruits of this ... research would have immediately transferred to hepatitis C sufferers in the U.S., including the one ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... for clevudine for the treatment of chronic hepatitis B infection, as well as increased preclinical development expenses for our second generation hepatitis C virus (HCV) product candidate, PSI-7851, and ... studies of clevudine for the treatment of chronic hepatitis B infection; On March 31, 2009, ...

Idenix Pharmaceuticals Reports First Quarter Financial Results

... 2009, data were presented from each of Idenix's hepatitis C programs at the annual meeting of the European ... Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, ... or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates, ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... Phase 3 trial of Albuferon (R) in chronic hepatitis C; global marketing applications planned in fall ... of two pivotal trials of Albuferon in chronic hepatitis C, and we plan global marketing applications in ... Two Phase 3 Trials of Albuferon (R) in Chronic hepatitis C; Late-Breaker Results of Both Phase 3 Trials ...

GeneNews to conduct joint project funded by MYR 5 million grant from Malaysian government

... diagnostic tests for liver cancer, hepatitis B and nasopharyngeal cancer - TORONTO, ... blood-based diagnostic tests for liver cancer, hepatitis B and nasopharyngeal cancer based on their ... Dr. Haji Mohd Ismail Merican. "Liver cancer, hepatitis B - a liver disease that can result in liver ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial ... Anadys is developing for the treatment of chronic hepatitis C virus (HCV) infection. Three Phase I trials, ... Non-Nucleoside Polymerase Inhibitor, In Chronic hepatitis C Patients," at the 44th Annual Meeting of the ...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

... diseases, today reported data from its three hepatitis C development programs being presented this week ... focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, ... programs or commercialization activities in hepatitis C, or any potential pipeline candidate. Such ...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ... to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements ...

Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables

... import and commercialize LG Life Sciences' hepatitis B vaccine, Euvax-B(TM), pursuant to the ... as awareness of the benefits of inoculations for hepatitis A and seasonal influenza increases across China. ... reflected increased sales of hepatitis A and hepatitis A&B vaccine in 2008. Net income for ...

Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results

... import and commercialize LG Life Sciences' hepatitis B vaccine, Euvax-B(TM), pursuant to the ... as awareness of the benefits of inoculations for hepatitis A and seasonal influenza increases across China. ... reflected increased sales of hepatitis A and hepatitis A&B vaccine in 2008. Net income for ...

Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008

... to commence in Q2. -- Launched the China hepatitis Internet Hospital ( http://www.zggbyy.com ... over-the-counter (OTC) treatment for hepatitis B. The increase in sales is also attributed to ... OTC product, and an estimated 120 million hepatitis B patients in China, we believe this product, in ...

Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference

... will present an overview of the company's three hepatitis C programs at the Canaccord Adams hepatitis C Conference on Tuesday, April 7 at 9:45 a.m. ET ... is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, ...

Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India

... of public health concern in that region, such as hepatitis E and Dengue fever. Cadila will contribute ... to India and the surrounding regions, including hepatitis E, chikungunya fever, dengue fever, and rabies. hepatitis E is a principal cause ...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

... and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer. The corporate ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...

Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)

... announced that four abstracts from the company's hepatitis C antiviral discovery and development programs ... Oral presentation; Parallel session entitled: hepatitis C Virus Drug Development II; Session date: ... focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation ... alfa-2a and Ribavirin in Patients with Chronic hepatitis C Virus (HCV). Incidence of ... A Mouse Model with Long Term Expression of hepatitis C Virus NS3/4A Protease for the Pharmacokinetic ...

AcroMetrix Announces the Release of OptiQuant-S Hepatitis C Virus (HCV) Panel

... with a critical component to fully optimize the hepatitis C molecular assays available in today's market. Viral hepatitis B and C now account for greater than 75% of all ... HCV represents our continued commitment to hepatitis C diagnostic testing," says Michael J. Eck, ...

Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round

... targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead ... and NS5A proteins will lead to uniquely effective hepatitis C treatments," said David Cory, President and CEO ... University and Director of the Center for hepatitis and Liver Tissue Engineering; he will serve as ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... Market Nitazoxanide for the Treatment of Chronic hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- ... of nitazoxanide as a treatment of chronic hepatitis C in Japan. Under the terms of the ... and marketing of treatments for chronic hepatitis C exemplified by their experience with Pegasys(R) ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... polymerase inhibitor for the treatment of hepatitis C, and advanced the drug candidate into ... Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, ... or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates, ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

... pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. ... drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. ... in the first of two Phase 3 trials in chronic hepatitis C; results of the second Albuferon Phase 3 trial ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) infection. In the phase II study in ... of Nitazoxanide for Treatment of Chronic hepatitis C," abstract FP052, was given by Emmet B. ... nitazoxanide tablet in patients with chronic hepatitis C genotype 1 later this year." In the Phase ...

Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets

... However, Insurance Coverage of hepatitis C Patients Is Skewed Towards Medicare and ... pharmaceutical and healthcare issues, finds that hepatitis C virus patient opportunity exists within many of ... have large bases of untreated patients. However, hepatitis C patients often lead high-risk lifestyles and ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... for clevudine for the treatment of chronic hepatitis B (HBV) infection, as well as increased ... of two oral antiviral molecules to treat hepatitis C virus (HCV) in the absence of interferon. The ... a leading franchise of nucleoside inhibitors for hepatitis C and B. Our plan is to provide updates ...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

... with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., Jan. 12 ... patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and ... ) "Patients undergoing treatment for chronic hepatitis C often find it challenging to participate in ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

... 2b trial with R7128, a nucleoside inhibitor of hepatitis C (HCV), slated to initiate in the first quarter ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...

FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C

... to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay. The test, ... HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, hepatitis C Virus RNA ...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg ... patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). Albinterferon alfa-2b is being ... interferon for the treatment of chronic hepatitis C, and we expect that global marketing ...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

... to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

... three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer. The presentation ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...
Other Contents
(Date:7/10/2014)... 27, 2014  The American Academy of Forensic ... Standards and Technology (NIST) and the Department of ... and forensic science expert members to the Forensic ... element of the NIST,s Organization of Scientific Area ... first appointments made to the new FSSB that ...
(Date:7/10/2014)... 1, 2014 Smart technology emphasis grows ... and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Visa Inc. ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... the second series of 30 second spots on CNBC for ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has announced ... company’s chief executive officer has announced a new promotion for ... at discounted prices, from 15 to 26 percent off. , ... huge demand in the current market. We are excited to ... lot of high quality products for sale. Many of our ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for agriculture in ... to maintain soil quality. The application of micro irrigation ... revenue generator for manufacturers in future. The trend of ... led to the adoption of micro irrigation techniques for ... demand for micro irrigation systems, as they reduce the ...
(Date:7/13/2014)... July 13, 2014 Fuel additives are ... gasoline, diesel, jet fuel, kerosene, and so on, in ... responsible for reducing the corrosion effects caused by fuels ... added to any fuel, provide economies of scale in ... escalate the overall cost of the fuel products. , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are ... to research presented today at the American Orthopaedic Society ... research marks the first of its kind investigating a ... events that occur after a head injury. , ... the (GT)n genotype were four times more likely to ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
Other TagsOther Tags